Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch

Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.

sales manager giving advice to his couple clients
Nabriva profiled customers based on CABP treatment priorities, seeking a differentiated Xentela launch approach. • Source: Shutterstock

Nabriva Therapeutics PLC has been preparing for two years to launch Xenleta (lefamulin), which the US Food and Drug Administration approved as an intravenous and oral treatment for community-acquired bacterial pneumonia (CABP) on 19 August. The company believes that it has laid the groundwork for a successful launch at a time when reimbursement for antibiotics finally may be moving in a positive direction, though there still is some skepticism about commercial prospects.

Nabriva's 60 sales representatives initially will target about 900 hospital and health care system accounts where physicians are looking to send CABP patients treated in the emergency department home with an oral antibiotic, treat patients with co-morbidities who have

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

Chinese Vaccine Makers Turn To Emerging Markets

 

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By 

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

More from Therapy Areas

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.